NCT01900054

A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: Tanabe Pharma Corporation · Industry
• Sex: All
• Age: 7 Years – 15 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the long-term safety and efficacy of TAU-284 (Bepotastine besilate) in pediatric patients with perennial allergic rhinitis for 12 weeks administration.

Detailed description

This is a multicenter,open-label, single-arm, uncontrolled study to evaluate the safety and efficacy of TAU-284 (20 mg/day) in pediatric patients with perennial allergic rhinitis for 12 weeks administration.

Conditions

• Perennial Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	Bepotastine besilate	Two TAU-284 5mg tablets will be taken orally twice a day

Timeline

• Start date: 2013-06-01
• Primary completion: 2013-11-01
• Completion: 2013-11-01
• First posted: 2013-07-16
• Last updated: 2026-01-07
• Results posted: 2015-12-14

Locations

1 site across 1 country: Japan